FrontPoint Decries Skowron’s Insider-Trading

Aug 18 2011 | 12:06pm ET

FrontPoint Partners has spoken out in the wake of the guilty plea of the man whose involvement in an insider-trading scandal brought the once-$7 billion hedge fund to its knees.

Joseph Skowron admitted that he sold shares of Human Genome Sciences after learning from a French doctor, who advised the pharmaceutical, that a hepatitis-C drug trial had produced disappointing results. By dumping FrontPoint’s 3.3 million shares of the company before the news became public, Skowron, the hedge fund’s former top healthcare fund manager, saved FrontPoint some $30 million.

“Dr. Chip Skowron now admits that, through his individual actions, he willfully violated FrontPoint’s principles, compliance policies and the code of conduct he signed,” FrontPoint said in a statement issued to “Dr. Skowron lied and misled FrontPoint’s internal compliance team, the external counsel hired to independently investigate his actions, and the federal government. FrontPoint was never accused of any wrongdoing and has fully resolved this matter with the government.”

Despite that, FrontPoint investors headed for the exits; in May, the firm announced that it would wind down most of its hedge funds, including its flagship strategy.

In Depth

Financial Industry Blockchain Consortium R3 To Open-Source Platform Code

Oct 20 2016 | 9:03pm ET

Bitcoin's blockchain technology has spawned a flurry of activity among fintech startups...


U.S. Trust's Beard: The Rapid Growth of the Art Lending Industry

Oct 7 2016 | 10:55pm ET

Alternative investment managers have emerged as some of the most significant art...

Guest Contributor

Hedge Fund Marketing – Tips for Your Initial Sales Meeting

Sep 29 2016 | 5:46pm ET

There are two main goals a hedge fund should have for an initial in-person sales...